BRPI0410679A - fórmulas de proteìna lìquida estabilizada em conteiners farmacêuticos cobertos - Google Patents

fórmulas de proteìna lìquida estabilizada em conteiners farmacêuticos cobertos

Info

Publication number
BRPI0410679A
BRPI0410679A BRPI0410679A BRPI0410679A BR PI0410679 A BRPI0410679 A BR PI0410679A BR PI0410679 A BRPI0410679 A BR PI0410679A BR PI0410679 A BRPI0410679 A BR PI0410679A
Authority
BR
Brazil
Prior art keywords
covered
liquid protein
stabilized liquid
pharmaceutical containers
protein formulas
Prior art date
Application number
Other languages
English (en)
Inventor
Fabrizio Samaritani
Alessandra Del Rio
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33442722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BRPI0410679A publication Critical patent/BRPI0410679A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/002—Closures to be pierced by an extracting-device for the contents and fixed on the container by separate retaining means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D51/00—Closures not otherwise provided for
    • B65D51/005—Closures provided with linings or internal coatings so as to avoid contact of the closure with the contents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

"FóRMULAS DE PROTEìNA LìQUIDA ESTABILIZADA EM CONTEINERS FARMACêUTICOS COBERTOS". Prevê um contêiner compreendendo um meio de fechamento coberto por um material fluorinado inerte e contendo uma composição líquida farmacêutica. Em particular, o contêiner compreende um meio de fechamento coberto com TEFLON e contém uma fórmula HSA-free Interferon-<225> com a seguinte composição: 30 a 100 <109>g/ml de Interferon-<225>, um agente de isotonicidade, 0.1 a 2 mg/ml de Poloxamer 188, ao menos 0.12 mg/ml de L-Metionina e uma solução tampão capaz de manter o pH da fórmula líquida a um valor entre 3.0 e 4.0.
BRPI0410679 2003-05-13 2004-05-12 fórmulas de proteìna lìquida estabilizada em conteiners farmacêuticos cobertos BRPI0410679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010671 2003-05-13
PCT/EP2004/050779 WO2004100979A2 (en) 2003-05-13 2004-05-12 Liquid stabilized protein formulations in coated pharmaceutical containers

Publications (1)

Publication Number Publication Date
BRPI0410679A true BRPI0410679A (pt) 2006-06-20

Family

ID=33442722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410679 BRPI0410679A (pt) 2003-05-13 2004-05-12 fórmulas de proteìna lìquida estabilizada em conteiners farmacêuticos cobertos

Country Status (22)

Country Link
US (2) US7540382B2 (pt)
EP (2) EP1633388B1 (pt)
JP (2) JP2007502684A (pt)
KR (1) KR101084412B1 (pt)
CN (1) CN1809376B (pt)
AR (1) AR044302A1 (pt)
AU (1) AU2004237982C1 (pt)
BR (1) BRPI0410679A (pt)
CA (1) CA2523477A1 (pt)
CY (1) CY1115233T1 (pt)
DK (1) DK1633388T3 (pt)
EA (1) EA008308B1 (pt)
ES (1) ES2471942T3 (pt)
HR (1) HRP20140267T1 (pt)
IL (1) IL171912A (pt)
MX (1) MXPA05012191A (pt)
NO (1) NO20055774L (pt)
PL (1) PL1633388T3 (pt)
PT (1) PT1633388E (pt)
SI (1) SI1633388T1 (pt)
UA (1) UA91493C2 (pt)
WO (1) WO2004100979A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA88300C2 (ru) * 2004-05-17 2009-10-12 Эйрес Трейдинг С.А. Гидрогелевые композиции, которые содержат интерферон
EA010979B1 (ru) * 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
CN107028760B (zh) * 2005-01-12 2019-11-01 比奥根Ma公司 运输干扰素-β的方法
JP2009502972A (ja) * 2005-07-29 2009-01-29 アムジエン・インコーポレーテツド タンパク質凝集を抑制する製剤
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
KR100785070B1 (ko) 2006-07-11 2007-12-12 삼성전자주식회사 휴대 단말기에서 디지털 저작권 관리 콘텐츠 재생 방법 및장치
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
BRPI0821029A2 (pt) * 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
BR112012013093A2 (pt) 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2882063T3 (es) 2012-12-03 2021-12-01 Novobiotic Pharmaceuticals Llc Nuevo depsipéptido y usos del mismo
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
EP4137139A1 (en) 2013-07-10 2023-02-22 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6685897B2 (ja) * 2014-03-13 2020-04-22 ステヴァナト グループ インターナショナル エイ．エス． 液体製剤を処理する方法
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
ES2871199T3 (es) 2015-09-24 2021-10-28 Matrix Biology Inst Composiciones de hialuronano de alta elasticidad y métodos de uso de las mismas
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
US11203616B2 (en) 2017-04-04 2021-12-21 Novobiotic Pharmaceuticals, Llc Depsipeptides and uses thereof
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2622598A (en) * 1951-03-08 1952-12-23 Premo Pharmaceutical Lab Inc Drain-clear container for aqueous liquid pharmaceutical preparations
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA2133962C (en) * 1992-05-06 2005-02-08 Robert G. Wolfangel Container and closure system for maintaining stability of sodium hypochlorite solutions
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW249202B (pt) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
TR199800811T2 (xx) * 1995-11-07 1998-07-21 Genentech,Inc. NGF i�in stabilize edici form�lasyonlar.
US6142977A (en) 1996-10-18 2000-11-07 Schering Ag Prefilled, sterilized syringe with a new and improved plug
SI0948358T2 (sl) * 1996-12-24 2012-03-30 Biogen Idec Inc Stabilne tekoče formulacije interferona
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CN2326243Y (zh) * 1997-09-29 1999-06-30 程继勇 覆膜药用瓶塞
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CN2441750Y (zh) * 2000-06-23 2001-08-08 程继勇 表面覆膜药用橡胶瓶塞
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
CN1133565C (zh) * 2001-10-18 2004-01-07 郑秀娣 药品瓶塞隔离膜

Also Published As

Publication number Publication date
CN1809376A (zh) 2006-07-26
US7540382B2 (en) 2009-06-02
USRE43331E1 (en) 2012-05-01
DK1633388T3 (da) 2014-04-07
NO20055774D0 (no) 2005-12-06
CY1115233T1 (el) 2017-01-04
EP1633388A2 (en) 2006-03-15
KR101084412B1 (ko) 2011-11-21
NO20055774L (no) 2005-12-06
ES2471942T3 (es) 2014-06-27
UA91493C2 (uk) 2010-08-10
SI1633388T1 (sl) 2014-05-30
HK1088558A1 (zh) 2006-11-10
MXPA05012191A (es) 2006-02-08
KR20060009913A (ko) 2006-02-01
WO2004100979A2 (en) 2004-11-25
CA2523477A1 (en) 2004-11-25
JP2007502684A (ja) 2007-02-15
CN1809376B (zh) 2010-04-28
AU2004237982B2 (en) 2010-03-04
IL171912A0 (en) 2006-04-10
AR044302A1 (es) 2005-09-07
PT1633388E (pt) 2014-06-25
AU2004237982C1 (en) 2018-03-08
HRP20140267T1 (hr) 2014-04-25
AU2004237982A1 (en) 2004-11-25
JP2012096063A (ja) 2012-05-24
EP2324845A1 (en) 2011-05-25
EA008308B1 (ru) 2007-04-27
IL171912A (en) 2015-02-26
WO2004100979A3 (en) 2005-05-19
PL1633388T3 (pl) 2014-08-29
EP1633388B1 (en) 2014-03-19
US20070092487A1 (en) 2007-04-26
EA200501692A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
MXPA05012191A (es) Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos.
AR092919A2 (es) Composicion farmaceutica liquida
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
BR0100554A (pt) Dispositivo de acondicionamento e de aplicação que possui uma estrutura porosa que incorpora um agente biocida
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
CA2201749A1 (en) Stable aqueous alfa interferon solution formulations
BRPI0408382A (pt) composição contendo materiais de zinco particulado que têm um tamanho definido de cristalito
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
WO2003007868A8 (en) Storage of liquid compositions
JP2007502684A5 (pt)
ZA200307161B (en) Medical aerosol formulations
BR0211736A (pt) Formulação para suspensão oral estabilizada
DE69912262D1 (de) Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
BRPI0410488A (pt) composição farmacêutica lìquida estabilizada livre de hsa, método para preparação de composição farmacêutica lìquida estabilizada livre de hsa, recipiente vedado hermeticamente e kit para administração de múltiplas doses de composição farmacêutica lìquida estabilizada livre de hsa&#39;
BRPI0408202A (pt) tampão embalado coberto de filme
AR037131A1 (es) Formulaciones de jarabe de ribavirina
WO2004039326A3 (en) Propofol with cysteine
DE60308899D1 (de) Quaternäre verbindungen enthaltend propolis als wirkstoff
ATE365037T1 (de) Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
BRPI0415082A (pt) método para a utilização de um material e recipiente de embalagem para a execução do método
BR9914031A (pt) Composições farmacêuticas micronizadas
AU774560B2 (en) Storage container for weakly acidic solution formulation containing human growth hormone, injection cartridge therefor and storage method therefor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]